Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review

Palleria, Caterina; Cozza, Giuseppe; Khengar, Rajeshree H.; Libri, Vincenzo; Sarro, Giovambattista De

doi:10.2174/1381612823666170809115429

Cited by 8 publications

(1 citation statement)

References 107 publications

(208 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, the central question becomes whether or not CBD is safe for consumers (children, elderly, patients) in large and unregulated quantities. Although there is only limited knowledge about the long-term effects of chronic use, or about drug-drug interactions between CBD and other medications [36], human studies have indicated that CBD is very well tolerated even up to a daily dose of 1,500 mg [37]. Indeed, a recent World Health Organization (WHO) review concluded that "to date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD" [38].…”

Section: Identifying the Real Risksmentioning

confidence: 99%

The Trouble with CBD Oil

Hazekamp¹

2018

Med Cannabis Cannabinoids

157

129

View full text Add to dashboard Cite

In just a few years, cannabidiol (CBD) has become immensely popular around the world. After initially being discovered as an effective self-medication for Dravet syndrome in children, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases. The cannabinoid CBD, a non-psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. There are currently dozens, if not hundreds, of producers and sellers of CBD oils active in the market, and their number is increasing rapidly. Those involved vary from individuals who prepare oils on a small scale for family and (Facebook) friends to compounding pharmacies, pharmaceutical companies, and licensed cannabis producers. Despite the growing availability of CBD, many uncertainties remain about the legality, quality, and safety of this new “miracle cure.” As a result, CBD is under scrutiny on many levels, ranging from national health organizations and agricultural lobbyists to the WHO and FDA. The central question is whether CBD is simply a food supplement, an investigational new medicine, or even a narcotic. This overview paper looks into the known risks and issues related to the composition of CBD products, and makes recommendations for better regulatory control based on accurate labeling and more scientifically supported health claims. The intention of this paper is to create a better understanding of the benefits versus the risks of the current way CBD products are produced, used, and advertised.

show abstract

Section: Identifying the Real Risksmentioning

confidence: 99%

The Trouble with CBD Oil

Hazekamp¹

2018

Med Cannabis Cannabinoids

157

129

View full text Add to dashboard Cite

show abstract

Efficacy and tolerability of lacosamide as adjunctive therapy in patients with focal-onset seizures: an observational, prospective study

et al. 2023

View full text Add to dashboard Cite

Purpose To evaluate the efficacy and tolerability of adjunctive lacosamide (LCM) in patients with focal-onset seizures, with or without combined secondarily generalized seizures. Methods 106 patients aged ≥ 16 years were recruited consecutively in this single-center prospective observational study. All patients received LCM as an add-on treatment on the basis of clinical judgement. Seizure frequency, adverse events (AEs) and retention rates were obtained at 3 and 6 months after LCM introduction. Result The overall response rates were 53.3 and 70.4% after 3 and 6 months, respectively, and the freedom of seizures at the same points was reached at 19 and 26.5%. The retention rates were 99.1% at the 3-month follow-up and 93.3% at the 6-month follow-up. The overall incidence of adverse events was 35.8%. The leading AEs were dizziness (16.98%) and sedation (6.6%). Conclusions Our study confirmed the efficacy and tolerability of adjunctive LCM in Chinese patients in real-life conditions. Based on our treatment experience, a universal maintenance dose of LCM would be needed in Chinese patients.

show abstract